What is the official website of Exom Group (now Kapadi) ?

The official website of Exom Group (now Kapadi) is https://exomgroup.com/.

What is Exom Group (now Kapadi)'s cybersecurity risk score?

Exom Group (now Kapadi) has an AI-generated cybersecurity risk score of 750 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Exom Group (now Kapadi) experienced?

According to Rankiteo, Exom Group (now Kapadi) currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Exom Group (now Kapadi) been affected by any supply chain cyber incidents ?

According to Rankiteo, Exom Group (now Kapadi) has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Exom Group (now Kapadi) have SOC 2 Type 1 certification ?

According to Rankiteo, Exom Group (now Kapadi) is not certified under SOC 2 Type 1.

Does Exom Group (now Kapadi) have SOC 2 Type 2 certification ?

According to Rankiteo, Exom Group (now Kapadi) does not hold a SOC 2 Type 2 certification.

Does Exom Group (now Kapadi) comply with GDPR ?

According to Rankiteo, Exom Group (now Kapadi) is not listed as GDPR compliant.

Does Exom Group (now Kapadi) have PCI DSS certification ?

According to Rankiteo, Exom Group (now Kapadi) does not currently maintain PCI DSS compliance.

Does Exom Group (now Kapadi) comply with HIPAA ?

According to Rankiteo, Exom Group (now Kapadi) is not compliant with HIPAA regulations.

Does Exom Group (now Kapadi) have ISO 27001 certification ?

According to Rankiteo,Exom Group (now Kapadi) is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Exom Group (now Kapadi) operate in ?

Exom Group (now Kapadi) operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Exom Group (now Kapadi) have ?

Exom Group (now Kapadi) employs approximately 11 people worldwide.

Does Exom Group (now Kapadi) own any subsidiaries ?

Exom Group (now Kapadi) presently has no subsidiaries across any sectors.

How many LinkedIn followers does Exom Group (now Kapadi) have ?

Exom Group (now Kapadi)'s official LinkedIn profile has approximately 16,489 followers.

What is the NAICS classification code for Exom Group (now Kapadi) ?

Exom Group (now Kapadi) is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Exom Group (now Kapadi) have a Crunchbase profile ?

No, Exom Group (now Kapadi) does not have a profile on Crunchbase.

Does Exom Group (now Kapadi) have a LinkedIn profile ?

Yes, Exom Group (now Kapadi) maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/exom-group.

How many cybersecurity incidents has Exom Group (now Kapadi) experienced ?

As of September 1, 2026, Rankiteo reports that Exom Group (now Kapadi) has not experienced any cybersecurity incidents.

How many peer or competitor companies does Exom Group (now Kapadi) have ?

Exom Group (now Kapadi) has an estimated 5,750 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Boost Score +25 with badge (5 left)

750

/1000

Fair

775

/1000

Fair

Exom Group (now Kapadi) Vendor Cyber Rating & Cyber Score

exomgroup.com

Add Your Compliance Badge

We are excited to announce that Exom Group has merged with OncoBay Clinical and Clinscience, and is now operating under a new unified brand: Kapadi. Therefore, the LinkedIn Profiles were merged as well: https://www.linkedin.com/company/kapadi/ This transformative merger brings together three companies' extensive expertise and resources, creating a premier provider of global technology- and data-driven oncology clinical trial services. By leveraging our combined strengths, Kapadi is uniquely positioned to support your future trials with unparalleled efficiency, innovation, and scientific excellence. We look forward to partnering with you to advance the development of novel cancer therapies and improve patient outcomes

EG A.I CyberSecurity Scoring

Scoring History

Exom Group (now Kapadi) CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

EG Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for EG

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Exom Group (now Kapadi) in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Exom Group (now Kapadi) in 2026.

Incident Types EG vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Exom Group (now Kapadi) in 2026.

Incident History - EG (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Exom Group (now Kapadi) Subsidiaries

Parent Company

EG

Pharmaceutical Manufacturing

Website: https://exomgroup.com/

Company Size: 11-50 employees

No subsidiary data available for this company.

Loading…

Exom Group (now Kapadi) Similar Companies

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Loading…

NEWS

Exom Group (now Kapadi) CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-83524

SUMMARY

A security vulnerability has been detected in RedPort Optimizer wXa-203, Optimizer wXa-213 and Optimizer wXa-223 up to 20260704. This impacts the function exec of the file /xgatev1/system/datetime.php of the component System Clock. The manipulation leads to command injection. The attack may be initiated remotely. The exploit has been disclosed publicly and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-08-31

Updated

Date2026-08-31

RISK INFORMATION (Score: 9.9)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.1

REFERENCES

CVE-2026-82971

SUMMARY

A vulnerability was determined in QVidium Opera11 3.3.2a26-Ax4x-opera11. This affects an unknown part of the file /cgi-bin/net_tr.cgi of the component CGI Script. This manipulation of the argument ipaddr causes command injection. The attack may be initiated remotely. The exploit has been publicly disclosed and may be utilized. The vendor explains: "QVidium has now closed its doors and no longer will be able to sell products or provide support." This vulnerability only affects products that are no longer supported by the maintainer.

Published

Date2026-08-31

Updated

Date2026-08-31

RISK INFORMATION (Score: 10)

cvss2

Base Score: 10.0

Complexity: LOW

AV:N/AC:L/Au:N/C:C/I:C/A:C

cvss3

Base Score: 10.0

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.9

REFERENCES

CVE-2026-82957

SUMMARY

A vulnerability was found in hyperledger-firefly firefly up to 1.4.0. The impacted element is the function ValidateOptions of the file internal/events/webhooks/webhooks.go of the component Webhook Subscription. Performing a manipulation of the argument url results in server-side request forgery. Remote exploitation of the attack is possible. The exploit has been made public and could be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-08-31

Updated

Date2026-08-31

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-82954

SUMMARY

A vulnerability was detected in Dokploy up to 0.29.7. This issue affects the function writeTraefikConfigInPath of the file packages/server/src/utils/traefik/application.ts of the component Settings. The manipulation of the argument path results in path traversal. The attack can be launched remotely. The exploit is now public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-08-31

Updated

Date2026-08-31

RISK INFORMATION (Score: 9.9)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.1

REFERENCES

CVE-2026-82922

SUMMARY

A security vulnerability has been detected in ShopEx ECShop up to 2.5.1. This vulnerability affects the function flow_update_cart of the file /flow.php?step=update_cart. The manipulation of the argument rec_id leads to sql injection. The attack can be initiated remotely. The exploit has been disclosed publicly and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-08-31

Updated

Date2026-08-31

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…